Immunoglobulin
Systemic Therapies
Once-weekly batoclimab lowers immunoglobulin for adults with uncontrolled Graves’ disease
Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant.
IVIG reduces skin thickening, gastrointestinal symptoms in systemic sclerosis
Intravenous immunoglobulin treatment may benefit skin, musculoskeletal and gastrointestinal manifestations of systemic sclerosis, with low risks for adverse events, according to data published in Seminars in Arthritis and Rheumatism.
Uplizna reduces IgG4 related disease flare risk by 87% in MITIGATE trial
The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.
VIDEO: Rh immunoglobulin shortage requires care in using existing supply
SAN FRANCISCO — In this video exclusive, Sarah Horvath, MD, MSHP, describes the current shortage of Rh immunoglobulin and outlines strategies for ethical use of the limited supply.
High total IgE, perennial aeroallergen specific IgE levels found in fatal asthma
WASHINGTON — Individuals who died due to asthma had high levels of total IgE and perennial aeroallergen-specific IgE, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
C1 inhibitor prevents adverse events from immunoglobulin replacement therapy
ANAHEIM, Calif. — A woman who could not tolerate immunoglobulin replacement therapy benefitted from C1-INH replacement therapy, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Immunoglobulin prevents infections associated with anti-BCMA therapy for multiple myeloma
Prophylactic IV immunoglobulin supplementation reduced the risk for severe infections by 90% among adults receiving a B-cell maturation antigen-directed bispecific antibody for treatment of multiple myeloma, study results showed.
Health care costs, resource use higher for patients with immunoglobulin A nephropathy
Health care costs and resource use were higher for patients with immunoglobulin A nephropathy who were at high-risk proteinuria and had decline in kidney function, newly published data show.
FDA approves Hizentra 50 mL prefilled syringes for primary immunodeficiency treatment
The FDA has approved 50 ml/10 gm prefilled syringes of Hizentra for treating patients with primary immunodeficiency aged 2 years and older and adults with chronic inflammatory demyelinating polyneuropathy, according to a press release.